624. Hodgkin Lymphomas and T/NK cell Lymphomas: T/NK Cell Lymphoma Relapsed Therapy
Steven M. Horwitz, Anastasia Nikitina, Nikita Kotlov, et al.
DR is highly active at R / R PTCL with an ORR of 58 percent and a CR of 42 percent. In addition, the tolerable DR provided an adequate response to allow frequent bridging to ASCT. In contrast to D alone, DR caused lower rates of transaminitis and had higher rates of CR. TET2 mutations and greater involvement of B cells predicted a response. TP53 mutations were only seen in NR. Biomarker-driven patient selection could further improve the ORR to DR.
Krimo Bouabdallah, Raphaëlle Aubrais, Loïc Chartier, et al.
The results of BBV in the treatment of R / R PTCL show a high response rate, a long DoR in responding patients and a very good outcome. Patients in CR eligible for transplant have the best outcome. Thus, in these high-risk lymphomas with limited treatment options, this combination is a good candidate for salvage therapy prior to transplant consolidation.
Thomas E. Witzig, Lubomir Sokol, Won Seog Kim, et al.
Tipifarnib has shown very encouraging efficacy in patients with CXCL12-expressing subtypes of PTCL (AITL and PTCL-CXCL12 +). The data show a tolerable safety profile.
Steven M. Horwitz, Tatyana A. Feldman, Jing C. Ye, et al.
A complete and sustained response to cerdulatinib has been observed in patients with the AITL / TFH subtype. This also applies to patients with repeated relapses and / or who were refractory to their last treatment. The substance has acceptable tolerability and clinical activity in PTCL. The benefit-risk profile appears to be favorable in this population. Exception: the PTCL-NOS subgroup, in which no response was observed. This subtype-specific activity motivates the identification of biomarkers in order to optimize patient selection.
Bradley M. Haverkos, Onder Alpdogan, Robert Baiocchi, et al.
In patients with R/R-EBV + lymphomas, particularly refractory T/NK-NHL, a heterogeneous group of aggressive lymphomas with a dismal outcome, Nstat plus VGCV showed promising efficacy with several lasting responses. The combination has a manageable toxicity profile and is well tolerated.
Henry S. Ngu, Stephen Parkin, David W. Scott, et al.
According to the authors, the results in the ITT R / R PTCLs are suboptimal: only about 1/3 of the patients have long-term survival. But if they receive an SCT, then more than half are still alive after 5 years. A third line of therapy can be a successful bridge to SCT. Then new active ingredients should be considered. Despite more refractory patients, the results with allo-SCT are encouraging.